Veri Medtech (VRHI) Files Registration Statement for Proposed Initial Public Offering
Veri Medtech (OTC: VRHI) filed a Form S-1 registration statement with the U.S. SEC on November 17, 2025 for a proposed initial public offering of Class A common stock.
The company has not disclosed the number of shares or price range; the offering is subject to market conditions and may not be completed. The securities cannot be sold until the registration statement is declared effective, and any offering will be made only by prospectus in compliance with securities laws. The release includes standard forward-looking statements and a disclaimer that company materials are informational and not investment advice.
Veri Medtech (OTC: VRHI) ha presentato una modulo di registrazione Form S-1 presso la SEC degli Stati Uniti il 17 novembre 2025 per una prevista offerta pubblica iniziale di azioni ordinarie di classe A.
L'azienda non ha divulgato il numero di azioni né l'intervallo di prezzo; l'offerta è soggetta alle condizioni di mercato e potrebbe non essere completata. I titoli non possono essere venduti finché la registrazione non sarà dichiarata efficace, e qualsiasi offerta sarà effettuata solo mediante prospetto in conformità alle leggi sui titoli. Il comunicato contiene dichiarazioni previsionali standard e una clausola di esclusione di responsabilità secondo cui i materiali dell'azienda sono informativi e non costituiscono consulenza sugli investimenti.
Veri Medtech (OTC: VRHI) presentó una declaración de registro Form S-1 ante la SEC de EE. UU. el 17 de noviembre de 2025 para una posible oferta pública inicial de acciones ordinarias de clase A.
La empresa no ha revelado el número de acciones ni el rango de precios; la oferta está sujeta a condiciones de mercado y puede no llevarse a cabo. Los valores no pueden venderse hasta que la declaración de registro sea efectiva, y cualquier oferta solo se hará mediante prospecto en cumplimiento de las leyes de valores. El comunicado incluye declaraciones prospectivas estándar y una nota de exención de responsabilidad de que los materiales de la empresa son informativos y no constituyen asesoramiento de inversión.
Veri Medtech (OTC: VRHI)는 미국 증권거래위원회(SEC)에 Form S-1 등록신고서를 2025년 11월 17일에 제출했으며, A클래스 보통주를 대상으로 한 예비 상장공개(IPO)를 제안했습니다.
회사는 주식 수나 가격대에 대해 공개하지 않았으며, 공모는 시장 상황에 좌우되며 성사되지 않을 수도 있습니다. 등록신고서가 효력을 발생시키기 전에는 증권을 매도할 수 없으며, 모든 공모는 증권법을 준수하는 기관문서인 증권신고서를 통해서만 이루어집니다. 발표에는 일반적인 미래지향적 진술과 회사 자료는 정보 제공용이며 투자 자문이 아님이라는 면책조항이 포함되어 있습니다.
Veri Medtech (OTC: VRHI) a déposé une déclaration d'enregistrement Form S-1 auprès de la SEC américaine le 17 novembre 2025 en vue d'une offre publique initiale proposée d'actions ordinaires de classe A.
L'entreprise n'a pas divulgué le nombre d'actions ni la fourchette de prix; l'offre est soumise aux conditions du marché et pourrait ne pas être réalisée. Les titres ne peuvent être vendus tant que la déclaration d'enregistrement n'est pas devenue efficace, et toute offre sera faite uniquement sur la base d'un prospectus en conformité avec les lois sur les valeurs mobilières. Le communiqué comprend des déclarations prospectives standard et une clause de non-responsabilité indiquant que les documents de la société sont informatifs et ne constituent pas un conseil en investissement.
Veri Medtech (OTC: VRHI) hat bei der US-Börsenaufsicht SEC am 17. November 2025 eine Form S-1-Registrierungsanmeldung eingereicht für eine vorgeschlagene Erstnotierung von Stammaktien der Klasse A.
Das Unternehmen hat weder die Anzahl der Aktien noch eine Preisspanne bekannt gegeben; das Angebot unterliegt Marktkonditionen und könnte nicht zustande kommen. Wertpapiere dürfen erst verkauft werden, wenn die Registrierungsanmeldung wirksam geworden ist, und ein etwaiges Angebot wird nur durch einen Prospekt im Einklang mit Wertpapiergesetzen durchgeführt. Die Mitteilung enthält standardmäßige zukunftsgerichtete Aussagen und einen Haftungsausschluss, dass die Unternehmensunterlagen informationshaltig seien und keine Anlageberatung darstellen.
Veri Medtech (OTC: VRHI) قد قدمت بيان تسجيل Form S-1 إلى هيئة الأوراق المالية الأمريكية (SEC) في 17 نوفمبر 2025 لطرح عام أولي مقترح من أسهم Class A العادية.
لم تكشف الشركة عن عدد الأسهم أو نطاق السعر؛ العرض يخضع لظروف السوق وقد لا يتم. لا يمكن بيع الأوراق المالية حتى يتم إعلان سريان بيان التسجيل، وأي عرض سيكون فقط من خلال نشرة اشتراك بما يتوافق مع قوانين الأوراق المالية. الشرح يتضمن تصريحات مستقبلية معيارية وإخلاء مسؤولية يفيد بأن مواد الشركة معلوماتية وليست نصيحة استثمارية.
- Filed Form S-1 for proposed IPO on Nov 17, 2025
- Initiates formal SEC process toward public market access
- No share count or price range disclosed
- Offering completion is not assured and subject to market conditions
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OTC Markets -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology platform, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The proposed offering will be made only by means of a prospectus. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
Company Information: The information provided on the company’s website, press releases, in related materials, and in any documents or communications distributed by Veri Medtech Holdings, Inc. (the “Company”) is for informational purposes only. Company information does not constitute an offer or solicitation to sell shares or securities in the Company or any related or associated entity. Any such offer or solicitation will be made solely through a Company offering memorandum or similar formal investment documentation, in strict accordance with the terms of all applicable securities laws and regulations.
No information, statements, or analyses presented on this site, on the Company’s website, or in any Company media, or in Company materials, are intended to form the basis of any investment decision, nor do they constitute investment advice, recommendations, or counsel. This material does not constitute or form part of — and should not be construed as — any offer for sale or subscription, or any invitation to offer to buy or subscribe for any securities, nor should it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment of any kind. The Company expressly disclaims any and all liability for any direct or consequential loss or damage arising directly or indirectly from: (i) reliance on any information provided here or in related materials; (ii) any error, omission, or inaccuracy in such information; or (iii) any action taken or decision made based on such information.
Forward-Looking Statements: Cautionary Note Regarding Forward-Looking Statements: This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Veri Medtech (OTC: "VRHI") and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
About Veri Medtech (OTC Markets: VRHI): Veri Medtech is a publicly-traded healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With a strong integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models. With a commitment to innovation and patient-centric care, Veri MedTech continues to expand its services and reach, aiming to make personalized healthcare more accessible and effective for all. For more information, please visit: www.VeriMedTech.com
About Veriheal: Veriheal, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), is a healthcare technology company on a mission to help people gain access to alternative medicine treatments. For more information, please visit: www.Veriheal.com
About DosePop: DosePop, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), provides a one-stop healthcare technology platform for mental and physical health, all designed to empower you to take charge of your well-being. From weight loss solutions to anti-aging, our treatments are backed by science and administered by licensed professionals. For more information, please visit: www.DosePop.com
About Global Telemedicine: The global telemedicine market size was valued at USD 114.98 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of
For Press inquiries: verimedtechpr@gmail.com
FAQ
What did Veri Medtech (VRHI) announce on November 17, 2025?
Has Veri Medtech (VRHI) disclosed the IPO price range or share count?
When can Veri Medtech (VRHI) begin selling shares in the IPO?
Does the Veri Medtech (VRHI) filing guarantee the IPO will happen?
Where will Veri Medtech (VRHI) provide official offering details for investors?
